Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2021 (6th edition). Gastric Cancer. 2023;26(1):1–25.

Article  Google Scholar 

Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303(17):1729–37.

Article  CAS  PubMed  Google Scholar 

Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet (London, England). 2019;393(10184):1948–57.

Article  PubMed  Google Scholar 

Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–20.

Article  CAS  PubMed  Google Scholar 

Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 2019;37(15):1296–304.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marubashi S, Takahashi A, Kakeji Y, Hasegawa H, Ueno H, Eguchi S, et al. Surgical outcomes in gastroenterological surgery in Japan: report of the national clinical database 2011–2019. Ann Gastroenterol Surg. 2021;5(5):639–58.

Article  PubMed  PubMed Central  Google Scholar 

Yu J, Huang C, Sun Y, Su X, Cao H, Hu J, et al. Effect of laparoscopic vs open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer: the CLASS-01 randomized clinical trial. JAMA. 2019;321(20):1983–92.

Article  PubMed  PubMed Central  Google Scholar 

Son SY, Hur H, Hyung WJ, Park YK, Lee HJ, An JY, et al. Laparoscopic vs open distal gastrectomy for locally advanced gastric cancer: 5-year outcomes of the KLASS-02 randomized clinical trial. JAMA Surg. 2022;157(10):879–86.

Article  PubMed  PubMed Central  Google Scholar 

Etoh T, Ohyama T, Sakuramoto S, Tsuji T, Lee SW, Yoshida K, et al. Five-year survival outcomes of laparoscopy-assisted vs open distal gastrectomy for advanced gastric cancer: the JLSSG0901 randomized clinical trial. JAMA Surg. 2023;158(5):445–54.

Article  PubMed  PubMed Central  Google Scholar 

Lei X, Wang Y, Shan F, Li S, Jia Y, Miao R, et al. Short-and long-term outcomes of laparoscopic versus open gastrectomy in patients with gastric cancer: a systematic review and meta-analysis of randomized controlled trials. World J Surg Oncol. 2022;20(1):405.

Article  PubMed  PubMed Central  Google Scholar 

Kaito A, Kinoshita T, Shitara K, Shibasaki H, Nishida T. Timing of initiation of adjuvant chemotherapy for gastric cancer: a case-matched comparison study of laparoscopic vs. open surgery. Eur J Surg Oncol. 2017;43(4):801–7.

Article  CAS  PubMed  Google Scholar 

Aoyama T, Yoshikawa T, Shirai J, Hayashi T, Yamada T, Tsuchida K, et al. Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer. Ann Surg Oncol. 2013;20(6):2000–6.

Article  PubMed  Google Scholar 

Yamashita K, Kurokawa Y, Yamamoto K, Hirota M, Kawabata R, Mikami J, et al. Risk factors for poor compliance with adjuvant S-1 chemotherapy for gastric cancer: a multicenter retrospective study. Ann Surg Oncol. 2017;24(9):2639–45.

Article  PubMed  Google Scholar 

Tsujimoto H, Kouzu K, Sugasawa H, Nomura S, Ito N, Harada M, et al. Impact of postoperative infectious complications on adjuvant chemotherapy administration after gastrectomy for advanced gastric cancer. Jpn J Clin Oncol. 2021;51(3):379–86.

Article  PubMed  Google Scholar 

Nakanishi K, Kanda M, Ito S, Mochizuki Y, Teramoto H, Ishigure K, et al. Delay in initiation of postoperative adjuvant chemotherapy with S-1 monotherapy and prognosis for gastric cancer patients: analysis of a multi-institutional dataset. Gastric Cancer. 2019;22(6):1215–25.

Article  CAS  PubMed  Google Scholar 

Miyatani K, Saito H, Shimizu S, Kono Y, Murakami Y, Shishido Y, et al. Late start and insufficient S-1 dose in adjuvant chemotherapy can lead to poor prognosis in stage II/III gastric cancer. Int J Clin Oncol. 2019;24(10):1190–6.

Article  PubMed  Google Scholar 

Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14(2):113–23.

Article  Google Scholar 

Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20(1):1–19.

Article  Google Scholar 

Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.

Article  PubMed  PubMed Central  Google Scholar 

U.S. Department of Health and Human Services NIoH, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_50

Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29(33):4387–93.

Article  CAS  PubMed  Google Scholar 

Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet (London, England). 2012;379(9813):315–21.

Article  CAS  PubMed  Google Scholar 

Yoshikawa T, Terashima M, Mizusawa J, Nunobe S, Nishida Y, Yamada T, et al. Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial. Lancet Gastroenterol Hepatol. 2019;4(3):208–16.

Article  PubMed  Google Scholar 

Kim W, Kim HH, Han SU, Kim MC, Hyung WJ, Ryu SW, et al. Decreased morbidity of laparoscopic distal gastrectomy compared with open distal gastrectomy for stage I gastric cancer: short-term outcomes from a multicenter randomized controlled trial (KLASS-01). Ann Surg. 2016;263(1):28–35.

Article  PubMed  Google Scholar 

Lee HJ, Hyung WJ, Yang HK, Han SU, Park YK, An JY, et al. Short-term outcomes of a multicenter randomized controlled trial comparing laparoscopic distal gastrectomy with D2 lymphadenectomy to open distal gastrectomy for locally advanced gastric cancer (KLASS-02-RCT). Ann Surg. 2019;270(6):983–91.

Article  PubMed  Google Scholar 

Takeoka T, Yamamoto K, Kurokawa Y, Miyazaki Y, Kawabata R, Omori T, et al. Comparison of the effects of open and laparoscopic approach on body composition in gastrectomy for gastric cancer: a propensity score-matched study. Ann Gastroenterol Surg. 2024;8(1):40–50.

Article  PubMed  Google Scholar 

Fujita S, Sakuramoto S, Matsui K, Ebara G, Nishibeppu K, Oya S, et al. Relative dose intensity and 1-year psoas muscle index reduction rate as prognostic factors in gastric cancer patients with postoperative adjuvant chemotherapy. Int J Clin Oncol. 2023;28(1):110–20.

Article  CAS  PubMed  Google Scholar 

Nishibeppu K, Komatsu S, Kosuga T, Kubota T, Okamoto K, Konishi H, et al. Cumulative total S-1 dose in adjuvant chemotherapy affects the long-term outcome following curative gastrectomy for gastric cancer. Am J Cancer Res. 2021;11(5):2312–8.

PubMed  PubMed Central  Google Scholar 

Jang SH, Jung YJ, Kim MG, Kwon SJ. The prognostic significance of compliance with postoperative adjuvant chemotherapy in patients with stage III gastric cancer: an observational study. J Gastric Cancer. 2018;18(1):48–57.

Article  PubMed  PubMed Central  Google Scholar 

Unger JM, Vaidya R, Albain KS, LeBlanc M, Minasian LM, Gotay CC, et al. Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials. J Clin Oncol. 2022;40(13):1474–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chou WC, Chang CL, Liu KH, Hsu JT, Cheng WH, Hsu HC, et al. Total gastrectomy increases the incidence of grade III and IV toxicities in patients with gastric cancer receiving adjuvant TS-1 treatment. World J Surg Oncol. 2013;11:287.

Article  PubMed  PubMed Central  Google Scholar 

Kano Y, Ohashi M, Hiki N, Takahari D, Chin K, Yamaguchi K, et al. Facilitated completion of 1-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer by medical oncologists. Surg Today. 2020;50(10):1197–205.